<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide, a novel immunomodulatory drug (IMiD), is a promising therapeutic strategy for patients with relapsed/refractory <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) and B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Biologically, the mechanisms responsible for lenalidomide activity are yet to be clearly defined </plain></SENT>
<SENT sid="2" pm="."><plain>Based on preclinical models and early correlative studies conducted in parallel to clinical trials, lenalidomide has been found to enhance natural killer (NK)- and T-cell activity against <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, alter the balance of pro- and anti-inflammatory cytokines in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> bed, inhibit <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and, to a lesser degree, induce cell cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Together, <z:hpo ids='HP_0000001'>all</z:hpo> of these biological effects appear to play a role in the activity observed in CLL or <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients treated with lenalidomide </plain></SENT>
<SENT sid="4" pm="."><plain>Given the effect in NK- and T-cell function, lenalidomide is an alternative strategy to enhance the antitumor activity of monoclonal antibodies (mAbs) </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical responses have been observed in patients with relapsed/<z:e sem="disease" ids="C0278791" disease_type="Neoplastic Process" abbrv="">refractory CLL</z:e>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) treated with lenalidomide single agent </plain></SENT>
<SENT sid="6" pm="."><plain>The favorable toxicity profile and route of administration made the use of lenalidomide an attractive therapy for certain types of patients (i.e. elderly, chemotherapy unfit, etc.) </plain></SENT>
<SENT sid="7" pm="."><plain>The erratic but serious incidence of <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> and/or <z:e sem="disease" ids="C0853891" disease_type="Disease or Syndrome" abbrv="">tumor flare</z:e> reactions provides challenges in the incorporation of lenalidomide in the management of previously untreated CLL or CLL/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients with bulky <z:mp ids='MP_0000702'>adenopathy</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Correlative studies and/or retrospective analysis of lenalidomide-treated patients had identified several biomarkers associated with clinical endpoints in CLL (i.e. changes in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha [TNF-Î±] or vascular endothelial growth factor [VEGF] levels) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (non-GCB phenotype) patients, but need to be validated </plain></SENT>
<SENT sid="9" pm="."><plain>Early studies evaluating the efficacy and toxicity of lenalidomide in combination with rituximab in previously untreated indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are promising and warrant further study </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, the evaluation of lenalidomide in the maintenance setting or in combination with other target-specific agents (i.e. <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi>) in aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> is being addressed in ongoing clinical trials </plain></SENT>
<SENT sid="11" pm="."><plain>In summary, lenalidomide is emerging as a biologically active and novel agent in the treatment of B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Future translational and clinical studies will further define the role of lenalidomide in the management of de novo or relapsed/<z:e sem="disease" ids="C0278791" disease_type="Neoplastic Process" abbrv="">refractory CLL</z:e> or B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and identify the subset of patients most likely to gain clinical benefit </plain></SENT>
</text></document>